CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Carbidopa

卡比多巴 杂质对照品Carbidopa Impurities

EP34 个杂质条目34 impurity entries

本页汇总 卡比多巴 的 34 个杂质对照品条目,其中药典杂质标注了 EP/USP 编号。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 34 impurity reference standards of Carbidopa with EP/USP numbering where applicable. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 卡比多巴(Carbidopa)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesChaotropic agents in liquid chromatographic method development for the simultaneous analysis of levodopa, carbidopa, entacapone and their impurities
    Journal of pharmaceutical and biomedical analysis · 2013 · Vemić A et al.  ·  PMID 23354116  ·  DOI
  2. 杂质研究Impurity studiesIntegrating Box-Behnken and Plackett-Burman designs for the robust impurity profiling of levodopa and carbidopa tablets
    Journal of pharmaceutical and biomedical analysis · 2026 · Korkmaz DA et al.  ·  PMID 42501458  ·  DOI
  3. 杂质研究Impurity studiesA rapid liquid chromatography/tandem mass spectrometry method for simultaneous determination of levodopa, carbidopa, entacapone and their six related compounds in film-coated tablets
    Rapid communications in mass spectrometry : RCM · 2020 · Burmaoğlu RE, Sağlık Aslan S  ·  PMID 32170976  ·  DOI

合成路线参考Reported synthetic routes

以下为公开文献中报道的合成方法(题录信息)。标题多已点明关键反应,可据此查阅原文了解完整路线与工艺条件。Published synthetic approaches. Titles usually name the key transformation; consult the original articles for full routes.

  • 合成方法SynthesisTrypsin mediated one-pot reaction for the synthesis of red fluorescent gold nanoclusters: Sensing of multiple analytes (carbidopa, dopamine, Cu(2+), Co(2+) and Hg(2+) ions)
    Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy · 2019 · Ghosh S et al.  ·  PMID 30840923  ·  DOI
  • 合成方法SynthesisAsymmetric synthesis of L-carbidopa based on a highly enantioselective α-amination
    Organic letters · 2013 · Pericas À et al.  ·  PMID 23477289  ·  DOI

卡比多巴 —— 原料药与杂质对照品Carbidopa — drug substance & impurities

共 34 个条目(含原料药本体)34 items incl. the drug substance
Carbidopa Impurity 1 Sesquihydrate (Carbidopa EP Impurity A  Sesquihydrate) structure
EPA
卡比多巴杂质1 倍半水合物 (卡比多巴EP杂质A 倍半水合物)Carbidopa Impurity 1 Sesquihydrate (Carbidopa EP Impurity A Sesquihydrate)
Carbidopa Impurity 1 Sesquihydrate (Carbidopa EP Impurity A Sesquihydrate)
CAS No.41372-08-1
Chemical FormulaC10H13NO4·3/2H2O
Purity>95%询价On request
10mg25mg50mg100mg
Carbidopa Impurity 1 (Carbidopa EP Impurity A) structure
EPA
卡比多巴杂质1 (卡比多巴EP杂质A)Carbidopa Impurity 1 (Carbidopa EP Impurity A)
Carbidopa Impurity 1 (Carbidopa EP Impurity A)
CAS No.555-30-6
Chemical FormulaC10H13NO4
Purity>95%询价On request
10mg25mg50mg100mg
Carbidopa Impurity 2 Hydrochloride (Carbidopa EP Impurity B Hydrochloride) structure
EPB
卡比多巴杂质2 盐酸盐 (卡比多巴EP杂质B 盐酸盐)Carbidopa Impurity 2 Hydrochloride (Carbidopa EP Impurity B Hydrochloride)
Carbidopa Impurity 2 Hydrochloride (Carbidopa EP Impurity B Hydrochloride)
CAS No.115054-62-1
Chemical FormulaC11H15NO4·HCl
Purity>95%询价On request
10mg25mg50mg100mg
Carbidopa Impurity 2 (Carbidopa EP Impurity B) structure
EPB
卡比多巴杂质2 (卡比多巴EP杂质B)Carbidopa Impurity 2 (Carbidopa EP Impurity B)
Carbidopa Impurity 2 (Carbidopa EP Impurity B)
CAS No.18181-08-3
Chemical FormulaC11H15NO4
Purity>95%询价On request
10mg25mg50mg100mg
Carbidopa Impurity 3 (Carbidopa EP Impurity C) structure
EPC
卡比多巴杂质3 (卡比多巴EP杂质C)Carbidopa Impurity 3 (Carbidopa EP Impurity C)
Carbidopa Impurity 3 (Carbidopa EP Impurity C)
CAS No.84488-77-7
Chemical FormulaC11H16N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Carbidopa Impurity 4 (Carbidopa EP Impurity D) structure
EPD
卡比多巴杂质4 (卡比多巴EP杂质D)Carbidopa Impurity 4 (Carbidopa EP Impurity D)
Carbidopa Impurity 4 (Carbidopa EP Impurity D)
CAS No.934371-48-9
Chemical FormulaC17H24N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Carbidopa Impurity 5 (Carbidopa EP Impurity E) structure
EPE
卡比多巴杂质5 (卡比多巴EP杂质E)Carbidopa Impurity 5 (Carbidopa EP Impurity E)
Carbidopa Impurity 5 (Carbidopa EP Impurity E)
CAS No.52514-63-3
Chemical FormulaC11H16N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Carbidopa Impurity 6 (Carbidopa EP Impurity F) structure
EPF
卡比多巴杂质6 (卡比多巴EP杂质F)Carbidopa Impurity 6 (Carbidopa EP Impurity F)
Carbidopa Impurity 6 (Carbidopa EP Impurity F)
CAS No.1458640-32-8
Chemical FormulaC12H18N2O4
Purity>95%询价On request
10mg25mg50mg100mg
rac-Carbidopa EP Impurity F HCl structure
EPF
rac- 卡比多巴EP杂质F盐酸盐rac-Carbidopa EP Impurity F HCl
rac-Carbidopa EP Impurity F HCl
CAS No.96115-88-7
Chemical FormulaC12H19ClN2O4
Purity>95%现货In stock
10mg25mg50mg100mg
Carbidopa Impurity 8 (Carbidopa EP Impurity H) structure
EPH
卡比多巴杂质8 (卡比多巴EP杂质H)Carbidopa Impurity 8 (Carbidopa EP Impurity H)
Carbidopa Impurity 8 (Carbidopa EP Impurity H)
CAS No.1361017-74-4
Chemical FormulaC11H16N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Carbidopa Impurity 10 (Carbidopa EP Impurity J) structure
EPJ
卡比多巴杂质10 (卡比多巴EP杂质J)Carbidopa Impurity 10 (Carbidopa EP Impurity J)
Carbidopa Impurity 10 (Carbidopa EP Impurity J)
CAS No.43197-33-7
Chemical FormulaC10H13BrN2O4
Purity>95%询价On request
10mg25mg50mg100mg
Carbidopa Monomer structure
—
卡比多巴 单体Carbidopa Monomer
Carbidopa Monomer
CAS No.28860-95-9
Chemical FormulaC10H14N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Carbidopa Impurity 5 structure
5
卡比多巴杂质5Carbidopa Impurity 5
Carbidopa Impurity 5
CAS No.54737-52-9
Chemical FormulaC11H14O5
Purity>95%现货In stock
10mg25mg50mg100mg
Carbidopa Impurity 6 structure
6
卡比多巴杂质6Carbidopa Impurity 6
Carbidopa Impurity 6
CAS No.210576-58-2
Chemical FormulaC4H3BrClNS
Purity>95%现货In stock
10mg25mg50mg100mg
Carbidopa Impurity 11 structure
11
卡比多巴杂质11Carbidopa Impurity 11
Carbidopa Impurity 11
CAS No.91908-71-3
Chemical FormulaC12H18N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Carbidopa Impurity 12 structure
12
卡比多巴杂质12Carbidopa Impurity 12
Carbidopa Impurity 12
CAS No.28875-92-5
Chemical FormulaC10H14N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Carbidopa Impurity 13 structure
13
卡比多巴杂质13Carbidopa Impurity 13
Carbidopa Impurity 13
CAS No.53832-94-3
Chemical FormulaC10H12O4
Purity>95%询价On request
10mg25mg50mg100mg
Carbidopa Impurity 14 structure
14
卡比多巴杂质14Carbidopa Impurity 14
Carbidopa Impurity 14
CAS No.32361-24-3
Chemical FormulaC9H11NO4
Purity>95%询价On request
10mg25mg50mg100mg
Carbidopa Impurity 15 structure
15
卡比多巴杂质15Carbidopa Impurity 15
Carbidopa Impurity 15
CAS No.579-27-1
Chemical FormulaC9H11NO4
Purity>95%现货In stock
10mg25mg50mg100mg
Carbidopa Impurity 16 structure
16
卡比多巴杂质16Carbidopa Impurity 16
Carbidopa Impurity 16
CAS No.1176784-51-2
Chemical FormulaC9H8N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Carbidopa Impurity 17 structure
17
卡比多巴杂质17Carbidopa Impurity 17
Carbidopa Impurity 17
CAS No.1246817-47-9
Chemical FormulaC10H13BrN2O4
Purity>95%询价On request
10mg25mg50mg100mg
Carbidopa Impurity 18 Monomer structure
18
卡比多巴杂质18 单体Carbidopa Impurity 18 Monomer
Carbidopa Impurity 18 Monomer
CAS No.85933-19-3
Chemical FormulaC11H16N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Carbidopa Impurity 19 structure
19
卡比多巴杂质19Carbidopa Impurity 19
Carbidopa Impurity 19
CAS No.1246819-09-9
Chemical FormulaC10H13BrN2O4
Purity>95%询价On request
10mg25mg50mg100mg
Carbidopa Impurity 21 structure
21
卡比多巴杂质21Carbidopa Impurity 21
Carbidopa Impurity 21
CAS No.1402053-59-1
Chemical FormulaC14H20N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Carbidopa Impurity 22 structure
22
卡比多巴杂质22Carbidopa Impurity 22
Carbidopa Impurity 22
CAS No.91431-01-5
Chemical FormulaC11H16N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Carbidopa Impurity 24 structure
24
卡比多巴杂质24Carbidopa Impurity 24
Carbidopa Impurity 24
CAS No.828-01-3
Chemical FormulaC9H10O3
Purity>95%询价On request
10mg25mg50mg100mg
Carbidopa Impurity 25 structure
25
卡比多巴杂质25Carbidopa Impurity 25
Carbidopa Impurity 25
CAS No.302-53-4
Chemical FormulaC10H14N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Carbidopa Impurity 28 structure
28
卡比多巴杂质28Carbidopa Impurity 28
Carbidopa Impurity 28
CAS No.319914-20-0
Chemical FormulaC10H12O3
Purity>95%现货In stock
10mg25mg50mg100mg
Carbidopa Impurity 29 Monomer structure
29
卡比多巴杂质29 单体Carbidopa Impurity 29 Monomer
Carbidopa Impurity 29 Monomer
CAS No.28860-96-0
Chemical FormulaC12H18N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Carbidopa Impurity 29 structure
29
卡比多巴杂质29Carbidopa Impurity 29
Carbidopa Impurity 29
CAS No.937203-35-5
Chemical FormulaC12H18N2O4·H2O
Purity>95%询价On request
10mg25mg50mg100mg
Carbidopa Impurity 31 structure
31
卡比多巴杂质31Carbidopa Impurity 31
Carbidopa Impurity 31
CAS No.2104012-68-0
Chemical FormulaC11H14O4
Purity>95%询价On request
10mg25mg50mg100mg
Carbidopa Impurity 33 structure
33
卡比多巴杂质33Carbidopa Impurity 33
Carbidopa Impurity 33
CAS No.1267993-22-5
Chemical FormulaC11H14N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Carbidopa Impurity 46 structure
46
卡比多巴杂质46Carbidopa Impurity 46
Carbidopa Impurity 46
CAS No.185339-56-4
Chemical FormulaC10H12N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Carbidopa Impurity 25-d5 structure
25-D5
卡比多巴杂质25-d5Carbidopa Impurity 25-d5
Carbidopa Impurity 25-d5
CAS No.1185134-76-2
Chemical FormulaC10H9D5N2O4
Purity>95%询价On request

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

卡比多巴 —— 研究文献与合成路线Carbidopa — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 卡比多巴 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Carbidopa. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Carbidopa suppresses prostate cancer via aryl hydrocarbon receptor-mediated ubiquitination and degradation of androgen receptor
    Chen Z, Cai A, Zheng H, et al. · Oncogenesis · 2020 · 被引 26cited 26
  2. Carbidopa suppresses estrogen receptor-positive breast cancer via AhR-mediated proteasomal degradation of ERα
    Chen Z, Xia X, Chen H, et al. · Investigational new drugs · 2022 · 被引 11cited 11
  3. Chaotropic agents in liquid chromatographic method development for the simultaneous analysis of levodopa, carbidopa, entacapone and their impurities
    Vemić A, Jančić Stojanović B, Stamenković I, et al. · Journal of pharmaceutical and biomedical analysis · 2013 · 被引 14cited 14
  4. Ascorbic acid can alleviate the degradation of levodopa and carbidopa induced by magnesium oxide
    Miyaue N, Kubo M, Nagai M · Brain and behavior · 2022 · 被引 7cited 7
  5. Integrating Box-Behnken and Plackett-Burman designs for the robust impurity profiling of levodopa and carbidopa tablets
    Korkmaz DA, Gençer P, Arabacı B · Journal of pharmaceutical and biomedical analysis · 2026
  6. Liquid chromatographic determination of levodopa, levodopa-carbidopa, and related impurities in solid dosage forms
    Ting S · Journal - Association of Official Analytical Chemists · 1986 · 被引 7cited 7

合成与制备工艺专利Synthesis & process patents

  1. Pharmaceutical preparation containing Entacapone, Levodopa and Carbidopa
    LUDWIG GERHARD DR, KRETZLER KAI DR · 公开号 EP2397121EP2397121 · 2011
  2. PROCESS FOR THE PREPARATION OF CARBIDOPA
    KATAINE FADGYAS KATALIN, FARKAS JANOS, LUKACS GYULA, LANG FERENC, et al. · 公开号 WO2007042848WO2007042848 · 2007
  3. PROCESS FOR THE PREPARATION OF CARBIDOPA
    KATAINE FADGYAS KATALIN, FARKAS JANOS DR, LUKACS GYULA DR, LANG FERENC, et al. · 公开号 HU0500940HU0500940 · 2007
  4. Green synthesis of carbidopa midbody
    WEIHUI ZHONG, LINGBO JIANG, XIAO CHEN, WEIKE SU · 公开号 CN101172960CN101172960 · 2008
  5. LEVODOPA/CARBIDOPA/ENTACAPONE PHARMACEUTICAL PREPARATION
    KALLIOINEN SARI, KERVINEN LASSE, LAAKSONEN MARJA, LINTULAAKSO JARMO, et al. · 公开号 JP2008156373JP2008156373 · 2008

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

卡比多巴 杂质谱研究要点Carbidopa — impurity profiling notes

下面这些是拿到 卡比多巴 的 34 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 34 impurity entries for Carbidopa, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

本品种含药典编号杂质(EP/USP)。申报时药典已收载的杂质通常需要逐项对照,建议优先备齐药典编号对照品,再补充工艺与降解杂质。This drug substance includes pharmacopoeially designated impurities (EP/USP). Monographed impurities normally need item-by-item comparison during filing, so secure the pharmacopoeial standards first, then fill in process and degradation impurities.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances